Eric H. Schoenstein
Jensen Investment Management
Eric H. Schoenstein Charles River Laboratories stake
total: 257
Jensen Investment Management CRL trades
- Total transactions:
- 10
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 4
- Held since:
- 2022 Q2
- Held for:
- 10 quarters
- Latest activity:
- 2024 Q4
According to 2026 Q2 report, Eric H. Schoenstein doesn't hold any Charles River Laboratories (CRL) shares. To date, the estimated cost basis is nearly $207.13 for "buy" trades and estimated average "sell" price is $205.41. Jensen Investment Management first purchased CRL in 2022 Q2, initially acquiring 8,660 shares. Since the initial investment in Charles River Laboratories (CRL), Jensen Investment Management has made 9 more transactions.
When did Eric H. Schoenstein sell Charles River Laboratories (CRL)?
Eric H. Schoenstein sold off the entire Charles River Laboratories (CRL) position in 2024 Q4.
When did Eric H. Schoenstein buy Charles River Laboratories (CRL)?
Eric H. Schoenstein first invested in Charles River Laboratories (CRL) in 2022 Q2 at the reported quarter-end price of $213.97 per share.
What's the cost basis of Jensen Investment Management's CRL stake?
The estimated cost basis for Charles River Laboratories (CRL) stake is around $207.13 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $207.12
- Weighted AVG sell price:
- $205.41
Eric H. Schoenstein's historical trades in Charles River Laboratories
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q4
|
0.00%
|
0
|
$196.97
|
|
-100% (-12,180)
|
-0.02%
|
|
2024 Q3
|
0.02%
|
12,180
|
$196.97
|
$2,399,095
|
-23.44% (-3,730)
|
-0.01%
|
|
2024 Q2
|
0.03%
|
15,910
|
$206.58
|
$3,286,688
|
-32.81% (-7,770)
|
-0.01%
|
|
2024 Q1
|
0.05%
|
23,680
|
$270.95
|
$6,416,096
|
-7.25% (-1,850)
|
-0%
|
|
2023 Q3
|
0.04%
|
25,530
|
$195.98
|
$5,003,369
|
+2.20% (+550)
|
+0%
|
|
2023 Q2
|
0.04%
|
24,980
|
$210.25
|
$5,252,045
|
-3.10% (-800)
|
-0%
|
|
2023 Q1
|
0.04%
|
25,780
|
$198.03
|
$5,105,213
|
+11.70% (+2,700)
|
+0%
|
|
2022 Q4
|
0.04%
|
23,080
|
$217.90
|
$5,029,132
|
+32.87% (+5,710)
|
+0.01%
|
|
2022 Q3
|
0.03%
|
17,370
|
$196.78
|
$3,418,000
|
+100.58% (+8,710)
|
+0.01%
|
|
2022 Q2
|
0.02%
|
8,660
|
$213.97
|
$1,853,000
|
new
|
+0.02%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.